Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

First things first: balancing hepatitis C and human immunodeficiency virus

Camilla S Graham, Margaret James Koziel

    Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
    |January 23, 2003
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPF.

    American journal of respiratory and critical care medicine·2026
    Same author

    Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.

    American journal of respiratory and critical care medicine·2026
    Same author

    Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia.

    Alimentary pharmacology & therapeutics·2026
    Same author

    A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults.

    ERJ open research·2026
    Same author

    Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.

    Lancet (London, England)·2026
    Same author

    Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.

    ERJ open research·2025